The Pharmaceutical Journal
Vol 269 No 7208 p133-134
27 July 2002

This page
Reprint
Photocopy

PDF* 55K

  The industry
  Cannabis
  Science in pharmacy
  ADR reporting
  Support staff
  Honorary auditors
  The Society
  Modernisation
  The Council

Letters to the Editor

The industry

Can we have an evidence base?

From Ms S. M Frederick, MRPharmS

Another advance for medicine — how thrilling to read that the S-enantiomer of citalopram has just been launched (PJ, 22 June, p867). Patients have been queuing up to tell me how wonderful new isomers of drugs are compared with the boring old isomers they were forced to make do with until the patents ran out. If spin-doctoring pharmaceutical molecules really does confer patient benefit (as well as shareholders) can we have an evidence base please? Because no patient has told me of any improvement to date, and I am feeling more cynical about, and ashamed of, the pharmaceutical industry by the day.

Sue Frederick
Maldon, Essex

Send your letter to The Editor

Next Topic (Cannabis)